If you are a device manufacturer dealing with the high cost of laboratory HPLC equipment — this project developed a plastic pillar array column that is much cheaper than packed bed columns and compatible with roll-to-roll manufacturing.
Low-Cost Point-of-Care Device for Accurate Diabetes and Hemoglobin Variant Monitoring
Imagine a tiny, plastic-based filter that sorts blood components like a high-tech sieve using swirling water patterns. This replaces expensive, bulky lab equipment with a cheap chip that can be mass-produced like a roll of stickers. It helps doctors get a clear picture of a patient's diabetes health, even for people with rare blood types that usually confuse standard tests.
What needed solving
Current gold-standard HbA1c tests are expensive, lab-bound, and inaccurate for 7% of the global population who carry hemoglobin variants. This leads to poor diabetes management and high healthcare costs.
What was built
A low footprint demonstrator featuring plastic pillar array columns fabricated via UV-nanoimprint lithography and a miniaturized detection system using UV absorption and SERS.
Who needs this
Who can put this to work
If you are a chip producer dealing with low precision in high-volume plastic fabrication — this project developed UV-nanoimprint lithography and plasma technology to create porous coatings with an aspect ratio of 4.
If you are a lab chain dealing with inaccurate HbA1c readings for the 7% of the population with hemoglobin variants — this project developed a system combining UV absorption and SERS detection for precise identification of analytes.
Quick answers
How does this reduce the cost of diabetes monitoring?
It replaces expensive packed bed columns with plastic pillar array columns that are compatible with mass roll-to-roll industrial manufacturing.
Can this be produced at an industrial scale?
Yes, the fabrication processes including UV-nanoimprint lithography, plasma technology, and lamination are designed to be scaled to roll-to-roll industrial manufacturing.
What is the IP or licensing status of the technology?
Based on available project data, specific patent or licensing details are not provided, though the project focuses on developing a low footprint demonstrator.
How does it integrate with existing blood sample workflows?
The system is designed as a low footprint instrument that allows for integrated sample preparation and miniaturized detection.
What is the timeline for market availability?
The project period runs from 2022-03-01 to 2026-02-28, suggesting the demonstrator is currently in development and testing phases.
Who built it
The consortium consists of 4 partners across 4 countries (AT, BE, EL, FR), showing a strong European research footprint. With a 25% industry ratio (1 industry partner, 1 university, and 2 research organizations), the project balances academic discovery with a clear path toward industrial application, specifically targeting roll-to-roll manufacturing.
Contact Vrije Universiteit Brussel regarding the VortexLC demonstrator
Talk to the team behind this work.
Contact us to explore licensing opportunities for the nanoimprint lithography process.